113 results about "Cannabinol" patented technology

The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications.

The present invention relates to a method for preparing a Cannabis plant Δ9-tetrahydrocannabinol isolate from a crude solvent extract of Cannabis plant material. The invention relates further to a Cannabis plant THC isolate comprising Δ9-tetrahydrocannabinol, Cannabinol (CBN) and / or Cannabidiol (CBD) and to a pharmaceutical composition comprising the Cannabis plant THC isolate.

The present invention pertains to methods for making compositions and compositions for treating pain and cachexia or AIDS wasting. In particular, the instant invention employs methods for making Δ9-tetrahydrocannabinol (Δ9-THC) and Δ9-tetrahydrocannabinolic acid (Δ9-THCA) from Cannabis sativa, and compositions for the treatment of these diseases.

The invention discloses a technology of extracting dihydrogen cannabinol from industrial cannabis sativa, and belongs to the technical field of biology. The technology comprises procedures of picking flowers and leaves, drying, crushing, soaking, extracting, concentrating and separating. The technology can implement complete recycle of media, and zero release and zero pollution for raw material classified extraction and waste comprehensive utilization. The technical processes from concrete extraction to separation of various substances as well as CBD purification all adopt international advanced technologies and meet international advanced standards.

The invention belongs to the technical field of chemical industry, and particularly relates to a method for enriching cannabidiol. The method includes steps of S1, drying Cannabis sativa flower and leaf for 0.5-4 hours at 120 DEG C, and smashing until the particle size of the smashed material meets the requirement of over 50 meshes; performing carbon dioxide supercritical extraction for 1-9 hours under the conditions of 30-55 DEG C and 13-30 MPa, and recycling carbon dioxide to obtain initial extractive of Cannabis sativa flower and leaf; S2, dissolving the initial extractive of Cannabis sativa flower and leaf in ethanol or methanol, refining, filtering and removing impurities, distilling and drying the solvent for future use; S3, filling a chromatographic column with the pretreated filler, sampling by a wet method or a dry method, wherein the sampling amount is 3-15 wt%; S4, performing gradient elution or isocratic elution by one or mixture of water, methanol, ethanol, n-butyl alcohol, acetone or chloroform; collecting the dilution section with enriched cannabidiol. The method is simple in technique; content of cannabidiol is improved, and tetrahydrocannabinol content is reduced.

The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.

The present invention provides a method for extracting cannabidiol, and belongs to the technical field of industrial extraction. The method comprises the following operation steps of drying the flowers and leaves of a mariguana plant, grinding and crushing, performing reverse extracting on the crushed coarse powder and a solvent in a reverse extracting device along the opposite directions, and enabling the solvent to extract the effective components of the coarse powder out of an extracting solution; performing pressure-relief heating on the extracting solution, and volatilizing the excessiveethanol in the extracting solution, so as to obtain a concentrated solution of cannabidiol; adding purified water into the concentrated solution of cannabidiol, diluting, eluting by a chromatography column in a gradient way, and collecting a target eluting solution; combining the target eluting solution, and performing pressure-relief concentrating at the temperature of 50 to 70 DEG C, so as to obtain a secondary concentrated solution of cannabidiol; adding 90%w / w ethanol over-saturated solution into the secondary concentrated solution of cannabidiol, obtaining a crystallized product, washingby the purified water, and drying, so as to obtain a cannabidiol product. The method has the advantages that the method can be applied to large-scale continuous production; the working is continuous without interruption; the output is high; the energy source is saved; the safety and reliability are realized.

The present invention is directed to the novel use of complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of α-CD, β-CD and γ-CD and a cannabinoid selected from the classical cannabinoid-group consisting of cannabinol, tetrahydrocannabinol and cannabidiol.

The invention discloses a preparation method of a cannabinol compound. The method comprises the following steps: screening industrial cannabis plant materials; drying and carrying out ultra-micro pulverization; putting the materials into an ultrasonic extraction device with a stirring function; adding a weak-polar or non-polar organic solvent and weak acid, and carrying out ultrasonic assisted extraction; filtering and adding active carbon in filtrate; filtering and evaporating to remove the solvent so as to obtain extractum of industrial cannabis extract; sufficiently dissolving the extractum by adopting a high-polar organic solvent; freeing, sealing, filtering and evaporating to remove the solvent, so as to obtain a primary product of the industrial cannabis extract; stirring the primary product and slowly adding an alkali solution; centrifuging and filtering; slowly adding an acid solution into filtrate; separating to obtain an industrial cannabis extract product containing the rich cannabinol compound. The method disclosed by the invention has the advantages of high extraction efficiency, low cost, few product impurities, small pollution and easiness of being industrially realized.

A method for preparing a purified cannabis extract may comprise extracting a crude extract from cannabis solids, dewatering the crude extract, removing chlorophyll from the crude extract, and distilling the crude extract thereby creating a purified cannabis extract. The extracting step may include contacting crude cannabis solids with an organic ester, thereby creating the crude extract and waste solids. The dewatering step may include contacting the crude extract with a solid dewatering agent and filtering the crude extract from the solid dewatering agent. The removing chlorophyll step may include contacting the crude extract with a solid absorbent agent, and filtering the crude extract from the solid absorbent agent.

The present invention relates to non-psychoactive derivatives of tetrahydro-cannabinol, which exhibit anti-inflammatory and analgesic activities. In particular, the present invention relates to methods of administering the derivatives and pharmaceutical compositions as therapeutic agents in the treatment of pain and tissue inflammation.

The invention belongs to the technical field of biotechnology, and particularly relates to a preparation method for industrial preparation and production of cannabidiol. The preparation method comprises the following steps: (1), adopting industrial hemp as a raw material and ethanol and water as solvents, and performing extraction and water extraction to obtain filtrate including components of theraw material; (2), performing solvent recovery on the obtained filtrate through a thin-film evaporator so as to obtain extract paste, and performing distillation on the extract paste to obtain cannabidiol-rich matter; and (3), separating and purifying the cannabidiol from the cannabidiol-rich matter by using column chromatography. Through the preparation method, environmental pollution is reduced, the process flow is simplified, the yield is improved, and the investment cost is reduced.

The invention provides competitive immunoassay techniques for high sensitivity detection of delta-9-tetrahydro-cannabinol (cannabis; THC) employing a carrier conjugate of an intermediate in the biosynthesis of cannabis, more particularly 5-pentylresorcinol conjugated to a macromolecular carrier via its hydroxyl groups. By employing such a conjugate with anti-THC antibody in a lateral flow immunochromatography test device convenient on-site testing for low levels of cannabis in liquid samples may be achieved. Such testing is particularly favoured for roadside testing for cannabis in oral fluid samples.

The present invention is directed to novel complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of RM-β-cyclodextrin, DM-β-cyclodextrin and TM-β-cyclodextrin, and a cannabinoid selected from the classical cannabinoid-group consisting of cannabinol, tetrhydrocannabinol and cannabidiol.

Terpene-enriched cannabinoid composition. Cannabinoid compositions are described including at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least three secondary terpenes; less than 5% by weight glycol; and less than 20% by weight water, where said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight / weight ratio in said composition is about 0.1 to about 1.0. Also described are the above compositions where said non-cannabinoid, non-terpene carrier comprise less than 5% by weight cellulose and the terpenes to cannabinoids weight / weight ratio in said compositions is about 0.05 to about 1.0, forming terpene-enriched cannabinoid compositions with enhanced therapeutic effect compared with that of a composition comprising the same cannabinoids amounts and one half the amount of said primary terpene.

The present invention is directed to novel complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of RM-β-cyclodextrin, DM-β-cyclodextrin and TM-β-cyclodextrin, and a cannabinoid selected from the classical cannabinoid-group consisting of cannabinol, tetrhydrocannabinol and cannabidiol.

The invention provides cannabinol derivatives and pharmaceutical preparations thereof.

The present invention relates to the use of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the treatment of multiple myeloma. The combination of THC and CBD appears to be particularly effective in reducing cell viability and cell migration in this disease. Preferably the THC and CBD are used is in the form of a highly purified extract of cannabis such that the cannabinoids are present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. Alternatively, the THC and CBD may be a synthetically produced cannabinoid.

The invention discloses the use of cannabinoid compounds or pharmaceutically acceptable salts thereof in the preparation of pharmaceutical compositions for the treatment of neurodermatitis, wherein the cannabinoid compounds can be selected from one of tetrahydrocannabinol, cannabinol, hypocannabinol and tetrahydrocannabinol, or the cannabinoid compounds can be selected from the group consisting of(1) a combination of tetrahydrocannabinol and tetrahydrocannabinol; (2) a combination of cannabinol and hypocannabinol; (iii) a combination of tetrahydrocannabinol and hypocannabinol; (4) a combination of cannabinol and tetrahydrocannabinol; (5) a combination of cannabinol, hypocannabinol and tetrahydrocannabinol; (6) a combination of tetrahydrocannabinol, hypocannabinol and tetrahydrocannabinol.

The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydro-cannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.

The invention belongs to the field of plant ingredient detection and particularly relates to a method for simultaneously detecting three cannabinol compounds in hemp with SPE-HPLC (solid phase extraction-high performance liquid chromatography). The SPE-HPLC is applied to detection of the cannabinol compounds in the hemp and can simultaneously detect the three cannabinol compounds in the hemp and perform qualitative and quantitative analysis on the compounds. According to the method, firstly, the HPLC conditions are determined, and a standard curve of the three cannabinol compounds is drawn anda linear regression equation is determined by detecting a mixed standard solution; a hemp sample is subjected to SPE for impurity removal, finally, high performance liquid detection is performed on the sample, and the content of the three cannabinol compounds in the hemp is obtained through calculation. To-be-detected cannabinol compounds and impurities are separated through SPE, influence of impurities on detection is reduced, and a good basis is provided for liquid detection. The detection method has a good linear relation in a corresponding application range and good precision, repeatability and accuracy.

The present invention relates to non-psychoactive cannabinol analogs of tetrahydrocannabinol, (3R,4R)-Δ8—THC-11-oic acids, for treating and preventing nausea and relieving symptoms thereof.

The invention relates to the technical field of detection, in particular to a qualitative and quantitative detection method of one or more of cannabidiol, cannabidiolic acid and tetrahydrocannabinol.The qualitative and quantitative detection method of one or more of the cannabidiol, the cannabidiolic acid and the tetrahydrocannabinol comprises the following steps that: ultrasound extraction is conducted on smashed hemp flower leaves through methyl alcohol, and a test solution is obtained; the test solution is separated and detected through high performance liquid chromatography, a moving phase of the high performance liquid chromatography is a mixture of acetic acid water solution and acetonitrile, and isocratic elution is conducted; and the content of one or more of the cannabidiol, thecannabidiolic acid and the tetrahydrocannabinol are detected through an external standard method. According to the qualitative and quantitative detection method of one or more of the cannabidiol, thecannabidiolic acid and the tetrahydrocannabinol, specific wave length and a moving phase are selected, the peak pattern is good, sensitivity is high, research is conveniently conducted, and qualitative and quantitative treatment of the cannabidiol, the cannabidiolic acid and the tetrahydrocannabinol can be detected quickly and accurately under treatment of the same sample.

The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and / or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.

The invention relates to a preparation method of cannabidiol crystals. The preparation method comprises following steps: 1, industrial hemp flower and leaf powder is subjected to decarboxylation and extraction so as to obtain a decarboxylation extracted product; 2, the decarboxylation extracted product is mixed with a first solvent, an obtained mixture is allowed to stand at a low temperature for precipitation, a precipitate is removed, the obtained solvent containing cannabidiol is subjected to concentration so as to obtain a concentrated extracted product; 3, the concentrated extracted product is mixed with a second solvent, filtering is carried out, an obtained filtrate is subjected to high pressure preparation liquid chromatogram treatment, a fraction containing cannabidiol is collected, and the solvent in the fraction is removed so as to obtain a cannabidiol crude product; and 4, the cannabidiol crude product is mixed with a crystallization solvent, and crystallization is carried out at a low temperature so as to obtain the cannabidiol crystasl. The preparation method is capable of obtaining the high purity cannabidiol crystals at a high total extraction rate, is low in energy consumption and organic solvent consumption amount, is capable of saving more energy, is more friendly to the environment, and is more specifically to be used in industrial applications.

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.